Federal Contractor Profile
Revagenix INC
$55M obligated·2 awards·1 agencies·1 NAICS
Federal Contracts
Showing award actions 1–16 of 16 funded award actions, most recent first.
- Contracts with positive obligations
- 2
- Funded award actions shown
- 16
- Obligations shown
- $55M
- Awarding agencies
- 1
This table shows award actions with a positive obligation. Zero-dollar and negative-dollar actions, such as administrative changes and deobligations, are not displayed. Multiple award actions may belong to the same contract.
Award data as of July 10, 2026. Source: USAspending federal award records.
| Date | Agency | PIID | NAICS | Description | Amount |
|---|---|---|---|---|---|
| May 6, 2026 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93022C00061 | 541715 | A NOVEL LPXC INHIBITOR WITH PAN-RESISTANT PSEUDOMONAS AND BURKHOLDERIA ACTIVITY. | $327K |
| Mar 23, 2026 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93022C00061 | 541715 | A NOVEL LPXC INHIBITOR WITH PAN-RESISTANT PSEUDOMONAS AND BURKHOLDERIA ACTIVITY. | $10.0M |
| Dec 30, 2025 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93022C00061 | 541715 | A NOVEL LPXC INHIBITOR WITH PAN-RESISTANT PSEUDOMONAS AND BURKHOLDERIA ACTIVITY. | $1.8M |
| Dec 23, 2025 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93020C00018 | 541715 | TO SELECT A NOVEL SMALL MOLECULE ANTIBIOTIC FOR CLINICAL DEVELOPMENT AND ADVANCE IT THROUGH IND FILING AND PHASE 1 CLINICAL STUDIES. | $2.1M |
| Apr 22, 2025 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93020C00018 | 541715 | TO SELECT A NOVEL SMALL MOLECULE ANTIBIOTIC FOR CLINICAL DEVELOPMENT AND ADVANCE IT THROUGH IND FILING AND PHASE 1 CLINICAL STUDIES. | $671K |
| Sep 10, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93022C00061 | 541715 | A NOVEL LPXC INHIBITOR WITH PAN-RESISTANT PSEUDOMONAS AND BURKHOLDERIA ACTIVITY. | $1.8M |
| Aug 5, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93022C00061 | 541715 | A NOVEL LPXC INHIBITOR WITH PAN-RESISTANT PSEUDOMONAS AND BURKHOLDERIA ACTIVITY. | $2.7M |
| Aug 1, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93020C00018 | 541715 | TO SELECT A NOVEL SMALL MOLECULE ANTIBIOTIC FOR CLINICAL DEVELOPMENT AND ADVANCE IT THROUGH IND FILING AND PHASE 1 CLINICAL STUDIES. | $3.8M |
| Mar 1, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93022C00061 | 541715 | A NOVEL LPXC INHIBITOR WITH PAN-RESISTANT PSEUDOMONAS AND BURKHOLDERIA ACTIVITY. | $6.7M |
| Feb 23, 2024 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93020C00018 | 541715 | TO SELECT A NOVEL SMALL MOLECULE ANTIBIOTIC FOR CLINICAL DEVELOPMENT AND ADVANCE IT THROUGH IND FILING AND PHASE 1 CLINICAL STUDIES. | $2.8M |
| Jan 13, 2023 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93020C00018 | 541715 | TO SELECT A NOVEL SMALL MOLECULE ANTIBIOTIC FOR CLINICAL DEVELOPMENT AND ADVANCE IT THROUGH IND FILING AND PHASE 1 CLINICAL STUDIES. | $5.1M |
| Sep 22, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93022C00061 | 541715 | A NOVEL LPXC INHIBITOR WITH PAN-RESISTANT PSEUDOMONAS AND BURKHOLDERIA ACTIVITY. | $4.8M |
| Jul 19, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93020C00018 | 541715 | TO SELECT A NOVEL SMALL MOLECULE ANTIBIOTIC FOR CLINICAL DEVELOPMENT AND ADVANCE IT THROUGH IND FILING AND PHASE 1 CLINICAL STUDIES. | $5.4M |
| Mar 29, 2022 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93020C00018 | 541715 | TO SELECT A NOVEL SMALL MOLECULE ANTIBIOTIC FOR CLINICAL DEVELOPMENT AND ADVANCE IT THROUGH IND FILING AND PHASE 1 CLINICAL STUDIES. | $1.3M |
| Jul 12, 2021 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93020C00018 | 541715 | TO SELECT A NOVEL SMALL MOLECULE ANTIBIOTIC FOR CLINICAL DEVELOPMENT AND ADVANCE IT THROUGH IND FILING AND PHASE 1 CLINICAL STUDIES. | $2.7M |
| Jun 29, 2020 | Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID | 75N93020C00018 | 541715 | TO SELECT A NOVEL SMALL MOLECULE ANTIBIOTIC FOR CLINICAL DEVELOPMENT AND ADVANCE IT THROUGH IND FILING AND PHASE 1 CLINICAL STUDIES. | $3.0M |
Get Alerted Before Revagenix INC's Next Recompete
Mindy monitors active contracts and flags recompetes 12 months out so you can position to compete.
Start for free